back to US directory
us clinical guidance

Type 1 diabetes in adults

ADA 2026 insulin, glucose technology, education, hypoglycemia, ketosis prevention and complication care for adults with type 1 diabetes.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with established type 1 diabetes and adults whose diabetes type is uncertain. ADA notes that adult classification can be difficult and misdiagnosis is common. This page addresses longitudinal core care; pregnancy, inpatient insulin, hyperglycemic crisis treatment, pancreas or islet transplantation and immunotherapy require separate protocols.
sources for this section:ADA Standards 2026

The Bottom Line

  • Treat established type 1 diabetes with physiologic insulin replacement using multiple daily injections or continuous subcutaneous infusion; never omit basal insulin because endogenous insulin deficiency creates ketosis risk.
  • Offer continuous glucose monitoring and, when appropriate and accessible, automated insulin-delivery technology with structured training, realistic expectations and a backup plan for device failure.
  • Individualize glucose and A1C goals from hypoglycemia risk, comorbidity, life circumstances and preference, and use time-in-range and hypoglycemia metrics when CGM is available.
  • Provide diabetes self-management education covering carbohydrate estimation, dose adjustment, exercise, alcohol, driving, illness, travel, reproductive planning and psychosocial burden.
  • Screen systematically for kidney, eye, nerve, foot, cardiovascular, autoimmune thyroid and other associated disease using the current Standards rather than focusing only on average glucose.
sources for this section:ADA Standards 2026

Practical clinical workflow

1
Confirm the diabetes history and phenotype, review autoantibody or C-peptide testing when classification remains uncertain, and identify any dangerous gap in insulin access immediately.
2
Review basal and mealtime insulin, injection or pump technique, CGM data, hypoglycemia, ketosis, meals, activity and affordability; reconcile every device and supply prescription.
3
Agree on individualized targets and adjust one interpretable pattern at a time, preserving basal coverage and checking whether technology settings, timing or carbohydrate assumptions explain excursions.
4
Ensure access to glucagon, ketone testing, rapid carbohydrate, backup insulin and written sick-day and pump-failure instructions; train close contacts where the person agrees.
5
Schedule complication screening and mental-health or eating-disorder review and connect the patient with endocrinology, diabetes education, nutrition and social support when needs exceed routine care.
sources for this section:ADA Standards 2026

Safety boundaries and escalation

  • Vomiting, abdominal pain, rapid breathing, dehydration, altered cognition or elevated ketones with hyperglycemia—or with an SGLT inhibitor despite less marked hyperglycemia—requires urgent DKA assessment.
  • Severe hypoglycemia, recurrent level 2 hypoglycemia or impaired awareness requires immediate regimen and safety review, glucagon access and temporary relaxation of targets when appropriate.
  • Do not prescribe an SGLT2 inhibitor as routine US type 1 diabetes treatment; check current FDA labeling and recognize euglycemic ketoacidosis risk.
  • Device malfunction, supply interruption, incarceration, housing instability or insurance loss can rapidly become life-threatening; create an executable backup and access plan before a crisis.
sources for this section:ADA Standards 2026

Localization

ADA Standards are living US recommendations and FDA device and insulin labels control product use. Insurer formularies, durable-equipment rules and state school or driving laws affect care but must not interrupt basal insulin.
sources for this section:ADA Standards 2026

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Diabetes Association Professional Practice Committee for DiabetesStandards of Care in Diabetes—20262026 Standards of Care, including living online updates · published 2025-12-08 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.